Clinical Edge Journal Scan

Multimorbidity disproportionately impacts women with RA


 

Key clinical point: Multimorbidity was more prevalent in women vs men with rheumatoid arthritis (RA), with psychological and musculoskeletal conditions being more prevalent in women and cardiovascular-related conditions being more prevalent in men, thus highlighting the need for individualized treatment plans.

Major finding: Among patients with RA age 18-50 years, women vs men were at higher risk for 2 morbidities (difference in adjusted absolute risk [Δ] 7.5 percentage points; P < .001) and 5 morbidities (Δ 4.4 percentage points; P < .001). Moreover, the prevalence of psychological and musculoskeletal conditions was higher in women vs men with RA, whereas the prevalence of cardiovascular-related conditions was higher in men vs women with RA (all P < .05).

Study details: This cross-sectional analysis of national administrative claims data from the OptumLabs Data Warehouse included 154,391 patients with RA who were matched with 154,391 comparator individuals without RA.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest. Two authors declared receiving unrelated funding support from various sources.

Source: Stevens MA et al. Disparities in multimorbidity and comorbidities in rheumatoid arthritis by sex acrossthe lifespan. Rheumatology (Oxford). 2023 (Aug 31). doi: 10.1093/rheumatology/kead454

Recommended Reading

Early glucocorticoid bridging in RA supported by meta-analysis, but concerns remain
MDedge Rheumatology
Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RA
MDedge Rheumatology
Tapering TNFi raises disease flare likelihood in patients with RA even in those in remission
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology
Factors associated with persistent fatigue in early RA
MDedge Rheumatology
Real-world study supports tocilizumab as first-line biologic in DMARD-IR patients with RA
MDedge Rheumatology
Tofacitinib + iguratimod offers choice for dual treat-to-target in RA with usual interstitial pneumonia
MDedge Rheumatology
Circulating semaphorin 4A shows potential for predicting treatment failure in RA
MDedge Rheumatology
JAKi offer a potential therapeutic option for mitigating bone loss in RA
MDedge Rheumatology